Galapagos provides a dual‑modality platform that discovers and develops both small‑molecule TYK2 inhibitors and stem‑like early‑memory CAR‑T cell therapies. Its lead TYK2 inhibitor GLPG3667 is in Phase 2/3 trials for systemic lupus erythematosus and dermatomyositis, while its decentralized CAR‑T system delivers vein‑to‑vein manufacturing in about seven days. The company licenses these assets to pharmaceutical and biotech partners for autoimmune and oncology programs.
Funding
Funding not disclosed
Founders
Product
Problem
Patients with immune‑mediated diseases (e.g., systemic lupus erythematosus, dermatomyositis) and certain cancers lack therapies that provide durable disease control and acceptable safety profiles, leading to high unmet medical need. Traditional drug development cycles are lengthy and often rely on external assets, limiting the speed at which novel mechanisms can reach patients.
Solution
Galapagos applies a dual‑modality platform that combines small‑molecule drug discovery with next‑generation cell‑therapy engineering to address these gaps. The company advances a selective TYK2 inhibitor (GLPG3667) through Phase 2/3 trials for autoimmune indications, while simultaneously developing stem‑like early‑memory CAR‑T products that can be manufactured in a decentralized, 7‑day vein‑to‑vein workflow. By partnering with external pharmaceutical and biotech firms, Galapagos licenses its assets, expands its pipeline, and accelerates the delivery of transformational medicines to patients.
Target Audience
Primary customers are pharmaceutical and biotechnology companies seeking to license or co‑develop innovative small‑molecule or cell‑therapy assets for autoimmune diseases and oncology, as well as clinical researchers focused on these therapeutic areas.
Features
- GLPG3667: a highly selective TYK2 small‑molecule inhibitor currently in Phase 2 for systemic lupus erythematosus and dermatomyositis, demonstrating statistically significant clinical benefit.
- Decentralized CAR‑T platform: stem‑like early‑memory T cells produced on‑site within a median of 7 days from apheresis to infusion, reducing manufacturing lead time and logistical complexity.
- Multi‑target discovery engine: integrated chemistry and biology capabilities that enable rapid identification of novel targets across immunology and oncology.
- Scalable manufacturing workflow: automated, functionally closed system (Cocoon®/xCellit®) with end‑to‑end quality‑control analytics for consistent product release.
- Partnership‑ready asset portfolio: clear in‑licensing and co‑development pathways for both small‑molecule and cell‑therapy candidates.
- Robust clinical‑trial infrastructure: global Phase 1‑3 programs compliant with FDA and EMA regulatory requirements, supported by a dedicated clinical‑operations team.